KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Deferred Revenue (2019 - 2021)

Xenon Pharmaceuticals (XENE) has disclosed Current Deferred Revenue for 6 consecutive years, with $2.2 million as the latest value for Q3 2021.

  • On a quarterly basis, Current Deferred Revenue fell 70.43% to $2.2 million in Q3 2021 year-over-year; TTM through Sep 2021 was $2.2 million, a 70.43% decrease, with the full-year FY2020 number at $3.6 million, down 87.76% from a year prior.
  • Current Deferred Revenue was $2.2 million for Q3 2021 at Xenon Pharmaceuticals, down from $3.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $29.7 million in Q4 2019 to a low of $2.2 million in Q3 2021.
  • A 3-year average of $10.9 million and a median of $5.5 million in 2020 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: crashed 87.76% in 2020, then crashed 70.43% in 2021.
  • Xenon Pharmaceuticals' Current Deferred Revenue stood at $29.7 million in 2019, then plummeted by 87.76% to $3.6 million in 2020, then plummeted by 39.54% to $2.2 million in 2021.
  • Per Business Quant, the three most recent readings for XENE's Current Deferred Revenue are $2.2 million (Q3 2021), $3.0 million (Q2 2021), and $3.6 million (Q1 2021).